Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label continuation study of ABT-874 in moderate to severe chronic plaque psoriasis
NL-OMON32696Phase 3Withdrawn
- Sponsor
- Abbott Laboratories
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of briakinumab in psoriasis, sponsored by Abbott Laboratories. Primary endpoints: Physician's Global Assessment, Psoriasis Area and Severity Index and 4 more. Planned start Nov 2008; status: withdrawn.
02
Drugs
briakinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON32696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32696.